EGFR and breast carcinoma: The expression of epidermal growth factor receptor (EGFR) in basal-like breast cancer is associated with poor prognosis [10-12] but more importantly, it provides the possibility to therapeutically target the receptor using either tyrosine kinase inhibitors (TKIs) or therapeutic monoclonal antibodies [13,14].